Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Saw that. Interesting that a CT order is filed right before pivotal data is to be released. Not sure what make of it? Maybe some kind if collaboration contingent upon positive data?
GLTA,
Murocman
Thank you!
Murocman
CERC anybody know what's going on?
Up 70% after hours but can't find any news.
Murocman
Have to be a subscriber to access $$$.
Murocman
Article mentioning Auris:
http://www.newsmax.com/Health/Health-News/ANNOTATED-BIZNEWS-BNALL-BNCOPY/2016/10/14/id/753412/
GLTA,
Murocman
Excellent point. While that type of anecdotal info doesn't guarantee they will meet their endpoint(s), it certainly is a very nice indicator that the drug effectiveness is headed that way. Thanks for the post!
GLTU
Murocman
Volume alert. Up on good volume on an otherwise bad market day. Something may be afoot.
GLTA,
Murocman
BGSM-Volume alert. This is a Napadano favorite. Promising technology and working with Mayo Clinic. It"s thinly traded normally so proceed accordingly.
GLTA
Murocman
Big volume spike all of a sudden. Just added more. GLTA!
Murocman
I think this can run to the $7-8 area short term. There is a fair bit of overhead resistance on the chart up to the $8 area. Hoewever, all of the volume today is helping to set it up for a run IMO.
GLTA,
Murocman
If you're close to a deal, you don't sell more shares. This is the activation of a previously filed shelf so no approval needed to dilute.
More likely they don't have any interest so are having to go it alone and dilute to resurrect their operations.
Murocman
In the last five trading days, 33 million shares have changed hands (float is 19 million) and the stock has moved from a low of $2.65 to a close of $4.38 yesterday.
All this on absolutely no news. That much movement doesn't happen for no reason. I don't think we're going to have to wait very long to find out what it will be given the kind of price-volume action we've experienced.
GLTA,
Murocman
How about the company just reports stellar results and the price rises to $4+ and uplisting will take care of itself! That would represent a market cap just north of $530M, which if this product proves to be as good as the company claims and early trial indicate ought be not be a stretch.
GLTA,
Murocman
Volume along with some buying interest today. On watch here.
Murocman
Nice, orderly consolidation of gains so far today!
GLTA,
Murocman
Saw that as well. Nothing like being in the right place at the right time with a game changing product. Sure helps underpin and highlight the value of the assets Sophiris has to offer.
GLTA,
Murocman
This is an excerpt from the June PR posted above:
All 18 patients enrolled completed the study. Biopsy data at six months following treatment showed that:
"Two men experienced complete ablation of their targeted tumor with no evidence of any tumor remaining at 6 months;
Seven men experienced a partial response, defined as either a reduction in the maximum cancer core length or a reduction in Gleason pattern;
Nine patients had no response to treatment."
Two patients cured is old news. The volume and move the last few days is not due to a re-hash of this news. Something much bigger, and so far unannounced, is in the offing.
It's actually better to see the stock moving like this on such high volume without news. It indicates the 'smart money' is buying and they can suck up a whole lot more shares than you and I. Enjoy the ride on their coat-tails. Hold until the big news or the smart money starts to decide to move elsewhere and profit handsomely. It's the William O'Neil way.
GLTU,
Murocman
Agreed. Something (good) has got to give soon. The company cut staff and is basically running in idle until some kind of buyout or partnership is in place.
GLTA,
Murocman
Big volume this morning with some large block trades. Bought some at $2.10.
GLTA,
Murocman
Worth a read as we approach results from Ph II:
https://blog.cirm.ca.gov/2016/01/13/new-stem-cell-treatment-for-als-slows-disease-progression/
Important to note this is not a cure but a therapy that will hopefully be effective in slowing or maybe even halting progression in some cases.
GLTA,
Murocman
Looking forward to seeing the PH II results here. The anecdotal evidence from the previous trials and articles published this Spring suggest the data will be positive. Probably not a cure, but anything that shows a significant slow down in the disease progression and improvement in QOL ought to be a big positive catalyst. If that proves to be the case, I don't think they will have a problem attracting capital and partners to take this to Phase III.
GLTA,
Murocman
Anyone have any idea on when the first results from the Ph I trial at UCL might be published. All I can find is the the trial is open label and is non-comparative---no information on number of patients or time to completion.
GLTA,
Murocman
Sheff sold out and likely many of his followers.
Murocman
Low float. Volatility and manipulation to be expected.
GLTA,
Murocman
The story here is not about earnings. Upcoming data for heart failure trial and start of Ph III trial for pain drug will drive the price, one way or the other.
GLTA,
Murocman
TL meeting at Zorinsky Lake. 3808 156th St, Omaha, Follow the entrance from the pool on 156th Street to the shelter.
Market is closed on Friday. Hoping for early approval here.
GLTA,
Murocman
Surprised there wasn't a PR issued today on the presentation last night.
Murocman
I'm long as well. Think this will move hard North in the next several trading days.
Murocman
I agree. Data will be good. Just depends if institutions and the broader market like it. Volume indicates they will.
Good luck to us!
Murocman
The conference PR hints at very strong data and volume is still strong. Has the makings of a very nice runner if the presented information is compelling.
Murocman
Right. One had to be very gutsy and quick to get the $55 price.
Went from sub $2 to just over $55 in two trading days early Aug 15 on positive data on secondary trial end points.
Stock had very low float. Major hedge fund (Baker Brothers) bought on the data release and sent the stock flying. It now trades back around $8. Trade this wisely.
GLTA,
Murocman
Could be an AQXP scenario here if the data is very good tomorrow.
GLTA,
Murocman
Good data for their Heart Failure therapy due before end Q1.
Saw a post on another board that SYN is supposed to have -004 data by end of Feb. Is that the DSMC interim review or something else? Can't find anything in latest presentation or news releases that says anything about end of Feb. all say H1 2016.
TIA,
Murocman
My gut says early approval as well; next week or early the last week of the month.
That said, my head is nagging my gut that the FDA has a negative bias towards this implant and therefore may drag things out to the PDUFA which means we probably won't see a press release until the 29th. I do think this gets approved regardless.
GLTA,
Murocman
How about you do just a little DD on your own! No the next catalyst is not approval. If you take just a little time to READ some of the very recent and informed posts on this board you'll readily figure out what the next catalyst is and the timing of it.
Yes I did. As documented exhaustively by TRUTH, the need for this is huge and I think the committee will overwhelmingly and enthusiastically support this submittal. If the tone lives up to my expectation and prediction, it should be very good for the stock.
GLTA,
Murocman
The notes will provide the committee and the public what the FDA is concerned about and what they would like the committee to focus on.
Based on the last ADCOM, I would expect it would be along the lines of issues, difficulties and problems associated with the actual implant and if the committee thinks what has been done as far as studies is safe, practical and something clinicians would be likely to do and patients would be willing to receive.
Also, the notes usually have a negative tone. The less so, the more bullish they are viewed.
GLTA,
Murocman